Oaknin, A., Gilbert, L., Tinker, A. V., Brown, J., Mathews, C., Press, J., . . . Pothuri, B. (2022). Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: Interim results from GARNET—a phase I, single-arm study. Journal for immunotherapy of cancer, 10(1), e003777. https://doi.org/10.1136/jitc-2021-003777
Chicago-Zitierstil (17. Ausg.)Oaknin, Ana, et al. "Safety and Antitumor Activity of Dostarlimab in Patients with Advanced or Recurrent DNA Mismatch Repair Deficient/microsatellite Instability-high (dMMR/MSI-H) or Proficient/stable (MMRp/MSS) Endometrial Cancer: Interim Results from GARNET—a Phase I, Single-arm Study." Journal for Immunotherapy of Cancer 10, no. 1 (2022): e003777. https://doi.org/10.1136/jitc-2021-003777.
MLA-Zitierstil (9. Ausg.)Oaknin, Ana, et al. "Safety and Antitumor Activity of Dostarlimab in Patients with Advanced or Recurrent DNA Mismatch Repair Deficient/microsatellite Instability-high (dMMR/MSI-H) or Proficient/stable (MMRp/MSS) Endometrial Cancer: Interim Results from GARNET—a Phase I, Single-arm Study." Journal for Immunotherapy of Cancer, vol. 10, no. 1, 2022, p. e003777, https://doi.org/10.1136/jitc-2021-003777.